Recurrent inactivating RASA2 mutations in melanoma

Nature Genetics

Volumn 47, Issue 12, 2015, Pages 1408-1410

  Arafeh, Rand ^a   Qutob, Nouar ^a   Emmanuel, Rafi ^a   Keren Paz, Alona ^a   Madore, Jason ^b,c   Elkahloun, Abdel ^d   Wilmott, James S ^b,c   Gartner, Jared J ^e   Di Pizio, Antonella ^f   Winograd Katz, Sabina ^a   Sindiri, Sivasish ^e   Rotkopf, Ron ^a   Dutton Regester, Ken ^g   Johansson, Peter ^g   Pritchard, Antonia L ^g   Waddell, Nicola ^g   Hill, Victoria K ^d   Lin, Jimmy C ^e   Hevroni, Yael ^a   Rosenberg, Steven A ^e   Khan, Javed ^e   Ben Dor, Shifra ^a   Niv, Masha Y ^f   Ulitsky, Igor ^a   Mann, Graham J ^b,c,h   Scolyer, Richard A ^b,c,i   Hayward, Nicholas K ^g   Samuels, Yardena ^a   more..

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^g QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CUTANEOUS MELANOMA; EXOME; GENE EXPRESSION; GENE INACTIVATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MELANOMA CELL; MOUSE; MUTATOR GENE; NONHUMAN; PRIORITY JOURNAL; RASA2 GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; GENETICS; HIGH THROUGHPUT SEQUENCING; MELANOMA; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; SKIN TUMOR; SURVIVAL RATE;

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RASA2 PROTEIN, HUMAN; TUMOR MARKER;

BIOMARKERS, TUMOR; EXOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MELANOMA; MUTATION; PROGNOSIS; RAS GTPASE-ACTIVATING PROTEINS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84949103421     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3427     Document Type: Article

References (24)

1. Siegel, R., Naishadham, D. & Jemal, A. CA Cancer J. Clin. 62, 283-298 (2012).
2. Hodis, E. et al. Cell 150, 251-263 (2012).
3. Krauthammer, M. et al. Nat. Genet. 44, 1006-1014 (2012).
4. Krauthammer, M. et al. Nat. Genet. 47, 996-1002 (2015).
5. Flaherty, K.T. et al. N. Engl. J. Med. 363, 809-819 (2010).
6. Chapman, P.B. et al. N. Engl. J. Med. 364, 2507-2516 (2011).
7. Lemmon, M.A. & Schlessinger, J. Cell 141, 1117-1134 (2010).
8. Vivanco, I. & Sawyers, C.L. Nat. Rev. Cancer 2, 489-501 (2002).
9. Sjöblom, T. et al. Science 314, 268-274 (2006).
10. Vogelstein, B. et al. Science 339, 1546-1558 (2013).
11. Maertens, O. & Cichowski, K. Adv. Biol. Regul. 55, 1-14 (2014).
12. Miao, W., Eichelberger, L., Baker, L. & Marshall, M.S. J. Biol. Chem. 271, 15322-15329 (1996).
13. Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M. & McCormick, F. Mol. Cell 22, 217-230 (2006).
14. Kiel, C., Verschueren, E., Yang, J.S. & Serrano, L. Sci. Signal. 6, ra109 (2013).
15. Ko, L.J. & Prives, C. Genes Dev. 10, 1054-1072 (1996).
16. Papa, A. et al. Cell 157, 595-610 (2014).
17. Fang, J.Y. & Richardson, B.C. Lancet Oncol. 6, 322-327 (2005).
18. Mann, G.J. et al. J. Invest. Dermatol. 133, 509-517 (2013).
19. Jayawardana, K. et al. Int. J. Cancer 136, 863-874 (2015).
20. Wei, X. et al. Nat. Genet. 43, 442-446 (2011).
21. Dutton-Regester, K. et al. Oncotarget 5, 2912-2917 (2014).
22. Palavalli, L.H. et al. Nat. Genet. 41, 518-520 (2009).
23. Solomon, D.A. et al. Cancer Res. 68, 10300-10306 (2008).
24. Scheffzek, K. et al. Science 277, 333-338 (1997).